The changes in LPS, TNF-α, and IL-6 in serum and liver shown in Figure 6, the correlation between pro-inflammatory cytokines and gut microbiota, and the changes in the TLR4 signaling pathway shown in Figure 7 demonstrate that MPGI prevents MASLD in obese mice by inhibiting inflammation through the regulation of gut microbiota dysfunction to reduce LPS production and the modification of the TLR4/NF-κB signaling pathway. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.